Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017 Apr 01; 35(10):1049-1060.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Chemotherapy, Adjuvant
Cyclophosphamide
Disease-Free Survival
Doxorubicin
Epirubicin
Female
Fluorouracil
Humans
Middle Aged
Neoadjuvant Therapy
Neoplasm, Residual
Paclitaxel
Phenotype
Prognosis
Prospective Studies
Receptor, ErbB-2
Receptors, Estrogen
Receptors, Progesterone
Risk Assessment
Survival Rate
Time Factors
Trastuzumab
Tumor Burden

authors with profiles

Kelly J. Hunt